Cargando…

Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer

SIMPLE SUMMARY: Historically, the treatment of prostate cancer was a blanket approach for all. Prostate cancer has not benefitted from targeted treatments based on specific tumour characteristics (ie. Particular genetic or molecular patterns) the way other cancers have. This is important as studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	McNevin, Ciara S., Cadoo, Karen, Baird, Anne-Marie, Murchan, Pierre, Sheils, Orla, McDermott, Ray, Finn, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616097/ https://www.ncbi.nlm.nih.gov/pubmed/34830851 http://dx.doi.org/10.3390/cancers13225697

Ejemplares similares

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer
por: McNevin, Ciara S., et al.
Publicado: (2021)

Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer
por: Greene, John, et al.
Publicado: (2021)

Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
por: Murchan, Pierre, et al.
Publicado: (2021)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
por: Lim, Marvin C. J., et al.
Publicado: (2021)

The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma
por: Dinneen, Kate, et al.
Publicado: (2021)

Carcinogenesis in prostate cancer: The role of long non-coding RNAs
por: Aird, John, et al.
Publicado: (2018)

Photorhabdus Species: Bioluminescent Bacteria as Human Pathogens?
por: Gerrard, John G., et al.
Publicado: (2003)

Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
por: Greene, John, et al.
Publicado: (2019)

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis
por: Nyberg, Tommy, et al.
Publicado: (2021)

Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic
por: Ahlborn, Lise B., et al.
Publicado: (2015)

ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer
por: Sheill, Gráinne, et al.
Publicado: (2023)

RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies
por: Lim, Marvin C. J., et al.
Publicado: (2018)

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
por: Li, Shuai, et al.
Publicado: (2022)

Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial
por: Brady, Lauren, et al.
Publicado: (2020)

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants
por: Dias, Alexander, et al.
Publicado: (2023)

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
por: Barnes, Daniel R, et al.
Publicado: (2021)

The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial
por: Sheill, Gráinne, et al.
Publicado: (2017)

Forensic Autosomal Short Tandem Repeats and Their Potential Association With Phenotype
por: Wyner, Nicole, et al.
Publicado: (2020)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
por: O’Shaughnessy, Megan, et al.
Publicado: (2023)

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
por: Momozawa, Yukihide, et al.
Publicado: (2022)

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
por: Silva, Romina, et al.
Publicado: (2021)

BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers
por: Osman, K., et al.
Publicado: (2023)

Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness
por: Flynn, Louise, et al.
Publicado: (2020)

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
por: Hakkaart, Christopher, et al.
Publicado: (2022)

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
por: Lee, Anbok, et al.
Publicado: (2020)

Dual BRCA1 and BRCA2 pathogenic variants in an adolescent with syndromic intellectual disability
por: Algouneh, Arash, et al.
Publicado: (2022)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

Use of Recombinant Mucin Glycoprotein to Assess the Interaction of the Gastric Pathogen Helicobacter pylori with the Secreted Human Mucin MUC5AC
por: Dunne, Ciara, et al.
Publicado: (2017)

The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma
por: Brennan, Shane, et al.
Publicado: (2021)

Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
por: Cotrim, Deborah Porto, et al.
Publicado: (2019)

Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)
por: Hayes, Brian, et al.
Publicado: (2021)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

FANCD2 limits replication stress and genome instability in cells lacking BRCA2
por: Michl, Johanna, et al.
Publicado: (2016)

The contribution of fisheries and aquaculture to the global protein supply
por: Boyd, Claude E., et al.
Publicado: (2022)

Prostate screening uptake in Australian BRCA1 and BRCA2 carriers
por: McKinley, Joanne M, et al.
Publicado: (2007)

BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
por: Kitson, Sarah J., et al.
Publicado: (2020)

Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants
por: Kang, Moonjong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f3urv2ni29bvap8t3m9k2rd56m